Stallergenes recalls allergy immunotherapy products

15 December 2015

French biopharmaceutical firm Stallergenes Greer (Euronext Paris: GENP) has been forced to shut down its site and recall every product released since August 13, it has been announced.

The problems have been caused by technical problems which have plagued the firm since it set up a new IT system at its allergy immunotherapy manufacturing plant in Antony.

Shares in Stallergenes fell by 20% after France’s regulator, l’Agence Nationale de Sécurité du Médicament (l’ANSM), raised concerns about the plant earlier this month.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK